Pfanstiehl Overview

  • Year Founded
  • 1919

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 99

Employees

  • Latest Deal Type
  • Debt

  • Financing Rounds
  • 4

Pfanstiehl General Information

Description

Manufacturer of low-endotoxin sugars intended for niche pharmaceutical and biotechnological industries. The company offers active pharmaceutical ingredients (APIs), including cytotoxic actives and sugars utilized as injectable excipients for cell culture media, protein stabilization and carbohydrates, enabling clients to get materials for large volume parenteral applications.

Contact Information

Formerly Known As
Ferro Pfanstiehl Laboratories
Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Corporate Office
  • 1219 Glen Rock Avenue
  • Waukegan, IL 60085-6230
  • United States
+1 (847)
Primary Industry
Other Pharmaceuticals and Biotechnology
Vertical(s)
Corporate Office
  • 1219 Glen Rock Avenue
  • Waukegan, IL 60085-6230
  • United States
+1 (847)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pfanstiehl Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pfanstiehl‘s full profile, request access.

Request a free trial

Pfanstiehl Patents

Pfanstiehl Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-7073349-B2 The solution(solute dissolved in a solvent) droplets are frozen by the temperature reduction that occurs simultaneously with the droplet atomization, and the droplets are freeze-dried under vacuum to sublime the frozen solvent. the frozen solvent is thus removed from the solute particles Inactive 07-Feb-2003
EP-1549410-A1 Composite particles and method for preparing Active 11-Oct-2002
EP-1549410-A4 Composite particles and method for preparing Active 11-Oct-2002
EP-1549410-B1 Method for preparing composite particles Inactive 11-Oct-2002
ES-2280850-T3 Procedure to prepare composite particles. Inactive 11-Oct-2002 B01D11/0411
To view Pfanstiehl’s complete patent history, request access »

Pfanstiehl Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pfanstiehl Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Pfanstiehl‘s full profile, request access.

Request a free trial

Pfanstiehl FAQs

  • When was Pfanstiehl founded?

    Pfanstiehl was founded in 1919.

  • Where is Pfanstiehl headquartered?

    Pfanstiehl is headquartered in Waukegan, IL.

  • What is the size of Pfanstiehl?

    Pfanstiehl has 99 total employees.

  • What industry is Pfanstiehl in?

    Pfanstiehl’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Pfanstiehl a private or public company?

    Pfanstiehl is a Private company.

  • What is Pfanstiehl’s current revenue?

    The current revenue for Pfanstiehl is .

  • How much funding has Pfanstiehl raised over time?

    Pfanstiehl has raised $13.9M.

  • Who are Pfanstiehl’s investors?

    Ferro has invested in Pfanstiehl.

  • When was Pfanstiehl acquired?

    Pfanstiehl was acquired on 02-Aug-2022.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process